The short answer
Aloe has not been shown to alter alogliptin absorption or effectiveness. Glucose improvements with aloe gel during a different diabetes regimen do not establish this interaction.
What this answer covers
Oral inner-leaf gel versus latex, whole-leaf and topical aloe; these are not interchangeable preparations.
- Supplement or preparation
- Aloe vera
- Medication ingredient
- alogliptin
The clinical study used other medicines
An aloe-gel trial with glyburide and metformin improved glucose measures and reported no adverse effects in its abstract. It did not involve alogliptin or measure its blood levels.
Different aloe products have different effects
Gel findings should not be assigned to latex or whole-leaf products. Latex can cause cramps and diarrhea; topical use does not establish the same exposure as swallowing an aloe product.
Glucose change is not an absorption result
A change in average glucose may reflect the supplement’s own effect. It does not prove that alogliptin was absorbed differently or worked less well. The drug can be taken with or without food.
Review the product and glucose response
Discuss starting or stopping the supplement with the diabetes team, and follow the prescribed monitoring plan. Do not change alogliptin yourself or assume a short spacing gap prevents a glucose effect. Kidney function, rather than a botanical enzyme theory alone, is central to its dosing.
Evidence and practical considerations
Absorption & effectiveness
No verified exact alogliptin clinical interaction. Original botanical preparations, other treatment regimens and null findings cannot establish the stated exposure/effectiveness or hypoglycemia claim.
- Exact scope
- Oral inner-leaf gel versus latex, whole-leaf and topical aloe; these are not interchangeable preparations. with Oral alogliptin RxCUI 1368001 IN supplied as benzoate; limited metabolism and renal elimination retained.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured event rate, imported CYP effect size or arbitrary dose adjustment.
Factors that may matter: Preparation; Kidney function; Other glucose-lowering medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alogliptin
DPP-4 inhibition produces glucose-dependent effects. Most dose is excreted unchanged in urine; CYP metabolism is limited. With or without food. Hypoglycemia precautions especially with insulin/secretagogues; renal function determines dosing.
How this applies: Exact alogliptin active-moiety bridge from current benzoate tablet label.
Not metformin/pioglitazone combination products. No exact botanical interaction rate or automatic nutrient requirement. Limited CYP role precludes simple probe-drug transfer.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 329 treatment-naive type 2 diabetes participants.
Alogliptin improved glycemic control; hypoglycemia and overall adverse-event proportions were similar across active and placebo groups.
How this applies: Exact alogliptin relevance limited by original exposure and endpoint.
Monotherapy does not establish supplement co-use safety or zero hypoglycemia.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Hyperlipidemic type2diabetes adults;30aloe and30placebo.
Aloe gel improved glucose measures with oral diabetes medicines; no adverse effects reported in the abstract.
How this applies: Indirect for alogliptin; original exposure and endpoint retained.
No alogliptin exposure or drug-level measurement. Oral gel, latex, whole-leaf and topical preparations differ; safety cannot be generalized.
Source 4: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering different Aloe vera products.
Guidance distinguishes oral preparations and describes limited glucose-lowering research; latex can cause abdominal pain, cramps and diarrhea.
How this applies: Indirect for alogliptin; original exposure and endpoint retained.
No alogliptin exposure or drug-level measurement. Oral gel, latex, whole-leaf and topical preparations differ; safety cannot be generalized.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact alogliptin article separating renal disposition, glucose effects and general husk timing. | |
| Research summary published |
Article revision: aa1a53c1100c355d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.